Approvals, rejections, priority reviews
30 stories
Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
Vera Therapeutics scores an accelerated approval for TRUTAKNA in IgA nephropathy, touting a 42% UPCR reduction vs placebo in Phase 3 ORIGIN 3. The dual BAFF/APRIL inhibitor enters a competitive market with a surrogate endpoint—investors await the confirmatory eGFR data.
The potential elimination of 280E taxes on cannabis businesses could inject over $2 billion annually into the biotech sector, accelerating cannabinoid drug development. MMJ International Holdings' latest press release quantifies the stakes.
The lack of a clear MAHA framework from the EPA creates uncertainty for biotech and pharma companies navigating chemical regulations, potentially affecting R&D investment, product approvals, and market positioning for bio-based alternatives.
Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
MindWalk’s European patent application for a high-dimensional biological data architecture could give it a proprietary platform for AI-native pharma R&D. The filing underscores a strategic pivot from model development to data infrastructure.
By filling 460+ faculty posts, AIIMS significantly expands its research capacity, positioning itself for breakthroughs in biomedical science. The influx of professors and early-career researchers will drive clinical trials, publications, and innovation, supported by a transparent blockchain-based selection process.
Philip Morris’s ZYN secured the first FDA modified risk orders for a nicotine pouch, authorizing reduced‑exposure marketing for 10 flavors. The decision sets a regulatory benchmark for oral nicotine products.
The U.S. Supreme Court ruled that FIFRA preempts state failure-to-warn claims against Bayer's Roundup, eliminating a massive source of litigation uncertainty. The 7-2 decision validates EPA's safety assessment of glyphosate and sharply reduces Bayer's outstanding tort exposure, potentially freeing up billions in capital for the biotech giant.
The DOJ’s operation specifically targeted fraudulent genetic testing schemes, sending shockwaves through biotech and pharma reliant on lab services. A new Data Fusion Center and $48.6M in settlements signal aggressive federal interest in precision medicine marketing.
Skin Analytics' Derm AI secures top European medical device approval with a landmark 99.8% melanoma detection rate, positioning it to reshape dermatology diagnostics.
Biotech company DIAGNOS executes a small debt-for-equity swap, preserving liquidity to sustain its AI-based early detection platform for critical eye conditions. The move reflects the tight capital environment for early-stage diagnostic innovators.
The FDA has established a novel product code for Solius Pro, an over-the-counter UVB light therapy device that claims to deliver biological benefits of sunlight with dramatically reduced risk. The move signals regulatory recognition of personalized home phototherapy as a distinct category.
The FDA’s approval of bemotrizinol, a chemical UV filter already widely used in other countries, represents a long-awaited regulatory milestone for the dermatology and OTC pharmaceutical industry. The decision signals a potential shift in the agency's approach to new sunscreen actives, with implications for ongoing GRASE reviews and future formulations.
Protagonist Therapeutics has transitioned from binary clinical risk to execution risk, with ICOTYDE's FDA approval and rusfertide's Priority Review. Backed by $620 million in cash, the company's validated peptide platform and royalty-based revenue model offer a compelling biotech investment thesis.
Biopharma companies face a potentially shrinking market and tougher FDA standards after Senate testimony highlighted 'very low certainty evidence' for pediatric gender treatments. With systematic reviews failing to show robust benefit, pipeline programs and commercial prospects for puberty blockers and cross-sex hormones are at risk.
Arizona has initiated criminal proceedings against prediction market Kalshi for alleged illegal betting, occurring simultaneously with a global market downturn triggered by Federal Reserve inflation warnings. In the pharmaceutical sector, Strides Pharma has issued a recall for children's ibuprofen, highlighting operational risks during a period of heightened regulatory and economic pressure.
Inovio (INO) reports FDA acceptance of its BLA for INO-3107 with a PDUFA date of October 30, 2026, though preliminary regulatory concerns regarding accelerated approval eligibility persist. Meanwhile, the company continues to manage a narrowing cash runway as it pivots toward commercialization.
The introduction of acoziborole, the first single-dose oral treatment for Human African Trypanosomiasis (sleeping sickness), marks a pivotal shift in global health efforts. Developed through a non-profit partnership between DNDi and Sanofi, the drug offers a simplified path to disease elimination by 2030.
Eli Lilly has issued a formal warning regarding "potentially dangerous" impurities discovered in compounded versions of its tirzepatide-based medications, Mounjaro and Zepbound. The company’s internal testing revealed significant safety risks in off-brand formulations, intensifying the ongoing conflict between big pharma and compounding pharmacies.
Japan has officially approved the world's first stem-cell-based treatment for Parkinson's disease, utilizing induced pluripotent stem (iPS) cells. The therapy, developed by Kyoto University and Sumitomo Pharma, marks a historic shift from symptom management to regenerative repair for neurodegenerative disorders.
GNTbm has received Investigational New Drug (IND) approval from the U.S. FDA to initiate Phase I clinical trials for its self-developed anti-cancer therapy, GNTbm-38. This milestone marks the company's formal entry into the U.S. clinical landscape, targeting advanced malignancies with its proprietary therapeutic candidate.
Optellum has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. The approval enables the deployment of the Virtual Nodule Clinic to help Australian clinicians identify and treat early-stage lung cancer more effectively.
The FDA has proposed a landmark regulatory framework to streamline the approval of customized, 'n-of-1' therapies for ultra-rare diseases. By shifting focus from individual products to validated manufacturing platforms, the agency aims to drastically reduce the time and cost of bringing genetic treatments to patients with unique mutations.
Disc Medicine has shifted its regulatory strategy for bitopertin in erythropoietic protoporphyria (EPP) following an FDA Complete Response Letter regarding its accelerated approval bid. The company will now focus on a traditional approval route, with pivotal Phase 2/3 APOLLO trial data expected in Q4 2026.
NG Biotech and partner Hardy Diagnostics have received FDA Breakthrough Device Designation for two rapid diagnostic tests targeting Candida auris and Acinetobacter baumannii. These assays aim to provide near-instant identification of high-priority antimicrobial-resistant pathogens to improve hospital infection control.
The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy.
The U.S. Food and Drug Administration is moving to eliminate the long-standing requirement for two pivotal clinical trials for new drug approvals. This regulatory shift aims to significantly reduce the time and cost of drug development, prioritizing faster patient access to innovative therapies.
ImmunityBio (IBRX) shares rallied following the European Commission's marketing authorization of ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer. This milestone marks the first international expansion for the IL-15 superagonist, significantly broadening its global commercial reach.
Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application.
According to our own tracking database, this category has accumulated 30 fda actions stories since coverage began. This page aggregates the latest fda actions stories within our biotech coverage area. Every story is cross-referenced across multiple primary sources, scored for sentiment and operational impact, and timestamped so fresh developments surface first. We track approvals, rejections, priority reviews and surface the angles a domain expert would actually read.
Story selection follows our editorial methodology — impact scoring weights regulatory, financial, and operational developments distinctly. Sentiment is classified across five tiers via supervised classification trained on labeled industry corpora. See our glossary for term definitions and our trends index for longitudinal patterns across the biotech beat.
| Signal | What it tells you |
|---|---|
| Verified by N sources | Confidence the story isn't a single-source rumor — N≥2 means the development is independently corroborated. |
| Impact score (1-10) | Estimated regulatory, financial, or operational impact. 8+ indicates a story experienced operators should act on. |
| Sentiment | Five-tier classification (very bullish through very bearish) trained on labeled biotech-specific corpora. |
| Time stamp | Recency. Fresh stories (under 1h) render with a highlighted timestamp; stale stories (≥24h) render dimmed. |